En vivo
FierceBiotechAffibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejectionFierceBiotechInsulet debuts latest enhancements to popular Omnipod insulin delivery systemPharmaVoiceBMS under pressure in schizophrenia; Summit/Akeso on a winning streakPromega BlogMeasuring What Matters in Metabolic Research: A Bioluminescent ToolkitBioWorldNME Digest: Q1 2026FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteranBioWorldNew York University identifies new analogues of mannose-6-phosphateBioWorldAvelos Therapeutics synthesizes new PARG inhibitorsBioWorldSimcere Zaiming Pharmaceutical discovers new MAPK inhibitorsLabiotechEight oncology deals in 2026 spotlight where industry leaders are betting bigEndpoints NewsFulcrum lays off majority of staff; Seres extends runway into 2027PharmaVoiceGSK, Takeda and others notch key clinical wins in tough-to-treat diseases
PharmaVoice 15 dic 2025

After years of debate, the Biosecure Act could be headed for Trump’s desk

After years of debate, the Biosecure Act could be headed for Trump’s desk

Original
Contenido no disponible. Consulta la fuente original.